Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crescent BiopharmaFRA:C68 +3.70%18 Debt-to-Equity is 0.01 as of Jun. 2026, which is at its 10-year median of 0.01. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 965 Biotechnology companies, Crescent Biopharma ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Crescent Biopharma's Debt-to-Equity or its related term are showing as below:
FRA:C68'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.42 Med: 0.01 Max: 0.02
Current: 0.01
During the past 2 years, the highest Debt-to-Equity Ratio of Crescent Biopharma was 0.02. The lowest was -2.42. And the median was 0.01.
FRA:C68's Debt-to-Equity is ranked better than 99.9% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs FRA:C68: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Crescent Biopharma Debt-to-Equity Related Terms
Crescent Biopharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:C68 vs ALLO, IMMX, NVCT: Debt-to-Equity Comparison
For the Biotechnology subindustry, Crescent Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma (FRA:C68) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Crescent Biopharma and its competitors. This is near median its historical median of 0.01. According to the industry distribution chart, Crescent Biopharma ranks #1 out of 965 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Crescent Biopharma's Debt-to-Equity too high?
Crescent Biopharma's current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.15. Crescent Biopharma's value of 0.01 is 93.3% below this industry median. Based on the distribution chart, Crescent Biopharma ranks #1 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Debt-to-Equity compare to ALLO and IMMX?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #1 out of 965 companies for Debt-to-Equity. This places Crescent Biopharma in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.15. Crescent Biopharma's value of 0.01 is 93.3% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.15, Crescent Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescent Biopharma's current Debt-to-Equity of 0.01 is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Crescent Biopharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescent Biopharma's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 93.3% below the Biotechnology industry median of 0.15. Crescent Biopharma's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score
Get the complete analysis for FRA:C68
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C68 has been successfully added to your 
